GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...

GlaxoSmithKline Pharmaceuticals Limited ... a second-generation anti-histamine and research product of UCB Pharma (Belgium) was launched under a co-marketing agreement. In the same year Glaxo ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Drug company executives on Tuesday touted their industry’s work to keep and make Americans healthy during a Washington event.

Embedding the patient voice into the DNA of a pharmaceutical company ... VP and country medical director, UK and Ireland at GSK, which has a dedicated Patients in Partnership team working to ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

The global Benign Prostatic Hyperplasia Surgical Treatment market, valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results. The post The GSK share price jumps 6% on positive FY 2024 results. Is it a ...